SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?


To: Jibacoa who wrote (9338)7/15/2005 8:42:44 AM
From: Galirayo  Respond to of 23958
 
[ZICA] Nice one Bernard.

How bout I add it ? Notice the Aroon Sergio. :)

stockcharts.com[w,a]dacayiay[dd][pb50!h.02,.20!f][vc60][iut!Ua12,26,9!Uv25]&pref=G

You still like VICL ??

stockcharts.com[w,a]dacayiay[db][pb50!h.02,.20!f][vc60][iut!Ua12,26,9!Uv25]&pref=G

It's Cleared the 50WMA again.
stockcharts.com[w,a]wacayiay[df][pb50!h.02,.20!f][vc60][iut!Ua12,26,9!Uv25]&pref=G

Check out STEM pre market .. VRrrrrroooommmm.

When's ASTM going to kick in? ClearStation didn't pound the Stop at 3.27 and it closed at 3.19.



To: Jibacoa who wrote (9338)7/15/2005 9:17:52 AM
From: Sergio H  Read Replies (2) | Respond to of 23958
 
Bernard, two questions on ZICA. Have they filled the CEO position or is it still interim? Lancer Offshore has filed to sell over 2 million shares. finance.yahoo.com Do you think this is just a bluff?

Thanks for your opinion on this stock.

Take a peek at this one if you have an opportunity. I know that it's out of your price range interest, but how do you like the trend reversal, not to mention the gaps.

stockcharts.com[w,a]dacayiay[db][pb50,10!b200!f][vc60][iut!Lv25!Lw25]&pref=G



To: Jibacoa who wrote (9338)7/18/2005 9:14:52 AM
From: Galirayo  Read Replies (1) | Respond to of 23958
 
7:05AM Vical begins Phase 1 trial of gene-based IL-2 with Inovio Electroporation technology (VICL) 4.82 :Inovio Biomedical (INO) and Vical (VICL) announce the initiation of a human Phase 1 study of an investigational method of delivering interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma.